P/E ratio for Axogen (AXGN)
P/E ratio as of May 2024 (TTM): -10.1
According to Axogen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.125. At the end of 2022 the company had a P/E ratio of -14.7.
P/E ratio history for Axogen from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -14.7 | 0.24% |
| 2021 | -14.6 | -50.93% |
| 2020 | -29.8 | 23.4% |
| 2019 | -24.2 | -29% |
| 2018 | -34.1 | -63.9% |
| 2017 | -94.3 | 382.15% |
| 2016 | -19.6 | 103.48% |
| 2015 | -9.62 | 165.16% |
| 2014 | -3.63 | -11.97% |
| 2013 | -4.12 | 28.15% |
| 2012 | -3.21 | 692.05% |
| 2011 | -0.4058 | -52.56% |
| 2010 | -0.8554 | -174.69% |
| 2009 | 1.15 | -110% |
| 2008 | -11.5 | 58.65% |
| 2007 | -7.22 | -0% |
| 2006 | -7.22 | 84.1% |
| 2005 | -3.92 | -249.08% |
| 2004 | 2.63 | -203.96% |
| 2003 | -2.53 | 222.61% |
| 2002 | -0.7846 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Medtronic MDT | 30.1 | -396.88% | 🇮🇪 Ireland |
 Thermo Fisher Scientific TMO | 37.4 | -469.28% | 🇺🇸 USA |
 Boston Scientific BSX | 88.5 | -973.83% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.